Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir,ribavirin,ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - dasabuvir sodium monohydrate,ombitasvir,paritaprevir dihydrate,ribavirin,ritonavir -

European Union - English - EMA (European Medicines Agency)

abbvie ltd - dasabuvir sodium - hepatitis c, chronic - antivirals for systemic use, - exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults. for hepatitis c virus (hcv) genotype specific activity.,

United States - English - NLM (National Library of Medicine)

abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825), dasabuvir sodium monohydrate (unii: og6d40m62l) (dasabuvir - unii:de54eqw8t1), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86), ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8) - ritonavir 33.33 mg - viekira xr is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration (2.2) and clinical studies (14)] : - genotype 1b infection without cirrhosis or with compensated cirrhosis - genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. - if viekira xr is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - viekira xr is contraindicated: in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions (5.2), use in specific populations (8.6) and clinical pharmacology (12.3)] . with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions (7) and clinical pharmac

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - dasabuvir sodium monohydrate - tablet - 250mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - dasabuvir sodium monohydrate -